Immune System Diseases

905 trials 381 recruiting

Filter these 905 trials by phase, country and sponsor.

Open in Search →

A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants with Severe Alopecia Areata Ended

2023-505061-82-01 Alopecia Areata 5 2024-06-17
Testing LADA diabetes status 3 years after treatment with intranodal GAD-alum. Ended

2023-509021-53-00 Latent Autoimmune Diabetes in Adults (LADA) 4 2024-06-05
A study to evaluate the efficacy and safety of JCAR017 in adult subjects with a type of cancer that affects B-cells, a type of white blood c… Ended

2024-510966-18-00 Relapsed or refractory indolent B-cell Non-Hodgkin Lymp 4 2024-06-03
Efficacy, Safety, and Pharmacokinetics of Guselkumab in Pediatric Participants with Moderately to Severely Active Ulcerative Colitis Ended

2022-502238-22-00 Ulcerative Colitis 5 2024-05-14
A Phase 3 Placebo-Controlled Study With Randomized Dose Up/Dose Down Extension Period Investigating the Efficacy, Safety, and Tolerability o… Ended

2022-502518-98-00 nonsegmental vitiligo 5 2024-04-26
A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis (REZOLV… Ended

2023-507456-69-00 Atopic Dermatitis 4 2024-04-25
A study to assess adverse events and effectiveness of upadacitinib oral tablets in adult and adolescent participants with vitiligo. Ended

2023-506195-27-00 non-segmental vitiligo 5 2024-04-05
TocilizuMab discontinuAtion in GIant Cell Arteritis Ended

2023-505515-21-00 Giant Cell Arteritis 5 2024-04-02
Effect of briquilimab in patients with patches of itching skin because of chronic spontaneous urticaria (CSU) despite treatment with antihis… Ended

2023-505446-25-00 Chronic Spontaneous Urticaria 9 2024-03-20
Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC): Evaluation of the Optimized Dose, Safety, and Efficacy of Livmoniplimab in Co… Ended

2022-502948-13-00 Hepatocellular Carcinoma 4 2024-03-01
ARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for Delayed Graft Function (Varvara) Ended

2022-503091-89-00 Delayed graft function 4 2024-02-15
A double-blind, placebo-controlled, randomized withdrawal study of canakinumab in pyogenic sterile arthritis pyoderma gangrenosum and acne (… Ended

2024-517155-13-00 PAPA syndrome 5 2024-02-02
ViaskinTM Peanut Immunotherapy Trial to Evaluate Safety, Simplicity and Efficacy (VITESSE) Ended

2022-502110-85-00 Peanut allergy 5 2024-01-18
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants with Moderate-to-Severe Thy… Ended

2023-503669-50-00 Moderate-to-Severe Thyroid Eye Disease 5 2023-12-27
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatm… Ended

2023-505120-59-00 Moderate to Severe Plaque Psoriasis 5 2023-12-19
An Open-Label Multicenter Phase 1b Study of Tolinapant (ASTX660) in Combination With Radiotherapy/Chemoradiotherapy (RT/CRT) in Preoperative… Ended

2024-511963-28-00 Neoadjuvant therapy in locally-advanced rectal cancer 3 2023-12-19
Immune response to the recombinant Zoster Vaccine in people living with HIV over 50 years of age compared to non-HIV age- and gender-matched… Ended

2023-504482-23-00 Human Immunodeficiency Virus (HIV) 4 2023-12-14
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatm… Ended

2023-505122-34-00 Plaque Psoriasis 5 2023-12-05
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants with Moderate-to-Severe Thy… Ended

2023-503309-13-00 Moderate-to-Severe Thyroid Eye Disease 5 2023-11-29
Trial of efficacy and safety of MC0518 versus best available therapy in patients with steroid-refractory acute graft versus host disease Ended

2023-503952-28-00 Steroid refractory Acute Graft versus host Disease 4 2023-11-13
A Phase 3b/4 Randomized, Double-Blind, Double-Dummy, Active Comparator-Controlled Study, Comparing the Efficacy and Safety of Upadacitinib V… Ended

2022-502578-18-00 Rheumatoid Arthritis 11 2023-11-07
A randomized, double-blind 2-arm NEPTUNUS extension study to assess the long-term safety and efficacy of ianalumab in patients with Sjögren’… Ended

2022-502966-26-01 Sjögren’s syndrome 5 2023-10-27
Phase 2 Placebo-controlled Study to Assess the Safety, Efficacy, and PK of ESK-001 in SLE Ended

2022-502105-15-00 Systemic lupus erythematosus 4 2023-10-20
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7507062 in Participants with Systemic Lupus Er… Ended

2022-502632-39-00 Systemic Lupus Erythematosus (SLE) 1 2023-10-11